Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

  title={Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition},
  author={G. Dresser and J. Spence and D. Bailey},
  journal={Clinical Pharmacokinetics},
  • G. Dresser, J. Spence, D. Bailey
  • Published 2000
  • Biology, Medicine
  • Clinical Pharmacokinetics
  • Drug interactions occur when the efficacy or toxicity of a medication is changed by administration of another substance. Pharmacokinetic interactions often occur as a result of a change in drug metabolism. Cytochrome P450 (CYP) 3A4 oxidises a broad spectrum of drugs by a number of metabolic processes. The location of CYP3A4 in the small bowel and liver permits an effect on both presystemic and systemic drug disposition. Some interactions with CYP3A4 inhibitors may also involve inhibition of P… CONTINUE READING
    816 Citations
    Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4
    • 45
    • PDF
    Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
    • 117
    Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
    • 176
    • PDF


    Inhibition and Induction of Cytochrome P450 and the Clinical Implications
    • J. Lin, A. Lu
    • Medicine, Biology
    • Clinical pharmacokinetics
    • 1998
    • 750
    • PDF
    Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
    • 326
    • PDF
    In vitro and in vivo drug interactions involving human CYP3A.
    • 791
    Carbamazepine drug interactions.
    • 57